Is Whitehawk Therapeutics, Inc. Common Stock profitable?

Whitehawk Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $115.8M over the trailing twelve months, a -288.3% net margin.

What are Whitehawk Therapeutics, Inc. Common Stock's profit margins?

Gross margin is 89.4% and operating margin is -1601.1%, with a -288.3% net margin.

What is Whitehawk Therapeutics, Inc. Common Stock's earnings per share?

Whitehawk Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.71.

Where does Whitehawk Therapeutics, Inc. Common Stock's income statement data come from?

Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Whitehawk Therapeutics, Inc. Common Stock WHWK Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23
Total revenue	$7.15M-72.5%	$25.98M+6.7%	$24.35M—
Total cost of revenue	$760K-74.9%	$3.02M+7.7%	$2.81M—
Gross profit	$6.39M-72.2%	$22.96M+6.6%	$21.55M—
Gross margin	89.4%+1.0pp	88.4%-0.1pp	88.5%—
Research and development	$90.96M+78.3%	$51.03M+4.3%	$48.93M—
Selling, general and administrative	$29.82M-18.8%	$36.75M-17.5%	$44.55M—
Total costs & expenses	$121.55M+30.1%	$93.44M-3.0%	$96.29M—
Operating income	-$114.4M-69.6%	-$67.46M+6.2%	-$71.93M—
Operating margin	-1,601.1%-1,341pp	-259.6%+35.7pp	-295.4%—
Interest income	$6.23M+58.8%	$3.93M-38.7%	$6.4M—
Other income (expense), net	$93.8M+2,390%	$3.77M-38.9%	$6.17M—
Gain (loss) on disposal of assets	$87.27M—	$0—	——
Income before income taxes	——	-$63.69M—	——
Income tax expense	——	$0—	——
Net income	-$20.6M+67.7%	-$63.69M+3.2%	-$65.77M—
Net margin	-288.3%-43.1pp	-245.1%+24.9pp	-270%—
Diluted earnings per share	$0.44+119%	-$2.36+3.3%	-$2.44—
Basic earnings per share	$0.45+119%	-$2.36+3.3%	-$2.44—
Weighted-average shares, diluted	240.1M+122%	108.1M+0.4%	107.6M—
Weighted-average shares, basic	239.8M+122%	108.1M+0.4%	107.6M—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$20.49M+67.8%	-$63.7M+2.9%	-$65.62M—
Gain on sale of business and assets	$87.27M—	$0—	——
Net unrealized gains (losses) on securities still held	——	-$11K—	——
Other income, net (Note 6)	$93.8M+2,390%	$3.77M-38.9%	$6.17M—
Revenue From Contract With Customer Excluding Assessed Tax	$7.15M-72.5%	$25.98M+6.7%	$24.35M—
EBIT	-$114.4M-69.6%	-$67.46M+6.2%	-$71.93M—
EBITDA	-$114.32M-70.0%	-$67.26M+6.3%	-$71.76M—
EBITDA	-$114.32M-70.0%	-$67.26M+6.3%	-$71.76M—
EBITDA margin	-1,600%-1,341pp	-258.9%+35.8pp	-294.7%—
EBIT	-$114.4M-69.6%	-$67.46M+6.2%	-$71.93M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Whitehawk Therapeutics, Inc. Common Stock profitable?: Whitehawk Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $115.8M over the trailing twelve months, a -288.3% net margin.
What are Whitehawk Therapeutics, Inc. Common Stock's profit margins?: Gross margin is 89.4% and operating margin is -1601.1%, with a -288.3% net margin.
What is Whitehawk Therapeutics, Inc. Common Stock's earnings per share?: Whitehawk Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.71.
Where does Whitehawk Therapeutics, Inc. Common Stock's income statement data come from?: Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.